Cytek Ordered to Pay Beckman Coulter $56 Million in Cell-Analysis Patent Case

What's Happening

A Delaware federal jury has ruled that Cytek Biosciences infringed a patent owned by Beckman Coulter, a Danaher company, involving technology used to analyze individual blood and tissue cells. The jury awarded Beckman $56 million, comprising $36 million in royalties and $20 million in lost profits, centering on Cytek's Aurora flow cytometers and related products.

What the Case Is About

Beckman Coulter sued Cytek in 2024, alleging that Cytek's products infringed patents covering flow cytometry technology. Flow cytometers are essential laboratory instruments used to analyze individual cells based on size, structure, and molecular markers for cancer research, immunology, hematology, drug development, and clinical laboratory testing. Cytek denied the allegations and challenged the validity of Beckman's patents.

What the Jury Decided

In a mixed verdict, the jury found that Cytek infringed one of the three patents at issue, while determining that the other two patents were not infringed and were invalid. The resulting financial assessment awarded Beckman $36 million in royalties and $20 million in lost profits, totaling $56 million.

Industry Impact

• Life Sciences: Organizations developing novel therapeutics and biologics rely extensively on advanced cell-analysis technologies during research and clinical development.
• Clinical Laboratories: Flow cytometry remains a foundational component of hospital and clinical laboratory infrastructure for diagnostics and hematology.
• Biotechnology: As single-cell analysis gains prominence in precision medicine, competition and IP protection among technology providers become increasingly vital.
• Medical Technology: The dispute underscores the high stakes of intellectual property protection within the diagnostics and life-sciences equipment market.

Looking Ahead

While Cytek has not yet indicated whether it will appeal the verdict, the outcome carries ongoing strategic implications for both companies as they compete within the high-value cell-analysis market.

Why This Matters

The $56 million verdict highlights the immense value of intellectual property in the rapidly expanding cell-analysis and life-sciences technology sector. As biomedical research shifts heavily toward precision medicine and single-cell platforms, accurate cellular characterization tools remain critical to drug discovery and diagnostics.

Key Takeaways

• A Delaware federal jury found Cytek Biosciences infringed a Beckman Coulter patent.
• Beckman Coulter was awarded $56 million ($36 million in royalties and $20 million in lost profits).
• The dispute involves flow cytometry technology used for single-cell blood and tissue analysis.
• The jury found two other patents at issue were not infringed and invalid.

What This Means for Healthcare Marketers

The case underscores the growing importance of cell analysis, laboratory diagnostics, precision medicine, and life-sciences research technologies. Companies operating in flow cytometry, single-cell analysis, laboratory equipment, biotech research, and clinical diagnostics continue to compete for healthcare and research organizations investing in advanced laboratory capabilities. For healthcare marketers, positioning advanced diagnostic tools and life-science solutions targets high-intent institutional buyers and researchers.